Stroke News

The term “metabolic syndrome” has been used since the mid-1990s to describe a constellation of risk factors that predispose adults to develop diabetes, CVD or both.

Shorter door-to-needle times lowered all-cause mortality and all-cause readmission at 1 year in patients aged at least 65 years with acute ischemic stroke treated with tissue plasminogen activator, researchers found.

Endovascular therapy for stroke due to anterior circulation large-vessel occlusion resulted in modestly better functional outcomes compared with medical therapy, even with presentation delay of more than 16 hours, researchers reported.

Absolute risk reduction for fatal and nonfatal strokes in patients who underwent early carotid endarterectomy was less than half the risk difference from trials initiated 20 years ago, researchers found.

Researchers observed a U-shaped trend in age-adjusted mortality rates from neurological disorders from 1999 to 2017. The recent upward trend suggests these disorders are an “imminent threat to public health,” they wrote in JAMA Neurology.

The FDA has accepted a biologics license application and granted priority review to a therapy shown to stabilize kidney function in patients with Fabry disease, according to a press release from Protalix BioTherapeutics.

Malnutrition, a common risk factor in patients with ACS, was strongly linked to increased CV events and mortality, researchers found.

Disparities in cardiometabolic mortality worsened between 1999 and 2017 between rural and urban Americans and within all race and sex groups for heart disease and diabetes, researchers found.

A shared decision-making encounter tool improved measures of quality including communication and knowledge in patients with nonvalvular atrial fibrillation considering anticoagulant treatment for stroke prevention, researchers reported.

There is no documented benefit of cannabis use for CVD prevention or treatment, according to a scientific statement from the American Heart Association.